Royal Bank of Canada
BMRN icon

Royal Bank of Canada’s BioMarin Pharmaceuticals BMRN Stock Holding History

Royal Bank of Canada’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,000
Closed -$144K – 6166
2014
Q3 		$144K Hold
2,000
– – ﹤0.01% 4412
2014
Q2 		$124K Hold
2,000
– – ﹤0.01% 4434
2014
Q1 		$136K Hold
2,000
– – ﹤0.01% 4371
2013
Q4 		$141K Sell
2,000
-12,600
-86% -$856K ﹤0.01% 4380
2013
Q3 		$1.05M Buy
+14,600
New +$970K ﹤0.01% 2719

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal Bank of Canada's BMRN Position: Q1 2026 in Review

Royal Bank of Canada reduced its BioMarin Pharmaceuticals (BMRN) stake by 56% in Q1 2026, selling an estimated $4.99M and leaving 68,309 shares worth $3.86M. The position accounts for ﹤0.01% of the portfolio, ranked #2605.

Royal Bank of Canada first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $23M in Q3 2025. 557 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Royal Bank of Canada held 68,309 shares of BioMarin Pharmaceuticals worth $3.86M as of Q1 2026.
  • Royal Bank of Canada sold 85,502 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $4.99M.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #2605 holding.
  • Royal Bank of Canada first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's BioMarin Pharmaceuticals position peaked at $23M in Q3 2025.
  • 557 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.